# Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

> **NCT01492426** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 605 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Telaprevir
- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01492426
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-12
- **Final completion:** 2014-03
- **Target enrollment:** 605 (ACTUAL)
- **Last updated:** 2016-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01492426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01492426, "Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01492426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*